Clinical Study

Phase II Investigation Of Adjuvant Combined Cisplatin And Radiation With Pembrolizumab In Resected Hnscc

Posted Date: Nov 9, 2016

  • Investigator: Trisha Wise-Draper
  • Co-Investigator: Trisha Wise-Draper
  • Specialties: Hematology/Oncology, Oncology, Cancer, Radiation Oncology
  • Type of Study: Drug

The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates your immune system to fight your cancer) to treatment that you will already be getting for your cancer. You will be offered “standa

Criteria:

To Be Eligible For This Study, Patients Must Have Head And Neck Cancer That Requires Surgery As Well As Post-Operative Radiation And Possibly Cisplatin.

Keywords:

Cancer, Head And Neck, Hnscc, Resected, Ucci-Hn-15-01

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.